| Pharmaceutical Information |
| Drug Name |
Tipranavir |
| Drug ID |
BADD_D02226 |
| Description |
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV. |
| Indications and Usage |
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AE09 |
| DrugBank ID |
DB00932
|
| KEGG ID |
D08605
|
| MeSH ID |
C107201
|
| PubChem ID |
54682461
|
| TTD Drug ID |
D0EV6T
|
| NDC Product Code |
0597-0003; 11014-0046; 12714-901 |
| UNII |
ZZT404XD09
|
| Synonyms |
tipranavir | tipranavir, (R-(R*,R*))-isomer | 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | Aptivus | tipranavir, (S-(R*,R*))-isomer | tipranavir, (S-(R*,S*))-isomer | tipranavir glucuronide | (2R)-3,6-Dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1R)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2H-pyran-4-yl beta-D-glucopyranosiduronic acid | tipranavir, (R-(R*,S*))-isomer | tipranavir C-14 | C14-tipranavir | 14C-tipranavir | tipranavir disodium | PNU-140690E | tipranavir sodium | PNU 140690 | PNU-140690 |
|
| Chemical Information |
| Molecular Formula |
C31H33F3N2O5S |
| CAS Registry Number |
174484-41-4 |
| SMILES |
CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=
CC=C4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Lipohypertrophy | 14.08.04.009; 23.07.01.005 | - | - | | | Hyperamylasaemia | 14.11.01.003 | - | - | Not Available | | Nail atrophy | 23.02.05.010 | - | - | Not Available |
|
|
|
